FTY720 pharmacokinetics in mild to moderate hepatic impairment

Journal of Clinical Pharmacology

Volumn 45, Issue 4, 2005, Pages 446-452

  Kovarik, J M ^a,b   Schmouder, R L ^a,b   Serra, D ^a,b   Wang, Y ^a,b   Wiegand, H ^a,b   Dilzer, S C ^a   Lasseter, K C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Clinical Pharmacology Associates ^*

Author keywords

Drug metabolism; FTY720; Hepatic impairment

Indexed keywords

BUTYRIC ACID; CALCIUM; CYANOCOBALAMIN; DIURETIC AGENT; DRUG METABOLITE; FINGOLIMOD; FOLIC ACID; FUROSEMIDE; HEXANOIC ACID; IMMUNOMODULATING AGENT; MULTIVITAMIN; SPIRONOLACTONE; THIAMINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASCITES; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; GRAFT REJECTION; HEART RATE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; NAUSEA; OPEN STUDY; ORGAN TRANSPLANTATION; SIDE EFFECT; SOMNOLENCE; XEROSTOMIA;

CASE-CONTROL STUDIES; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 16844364903     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004274288     Document Type: Article

References (11)

1. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296:346-349.
2. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453-21457.
3. Tedesco-Silva H, Mourad G, Khan BD, et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2a study in de novo renal transplantation. Transplantation. 2004;77:1826-1833.
4. Kahan BD, Tedesco H, Lorber MI, et al. FTY720 in combination with everolimus: a novel CNI-gree regimen as effective in Afro-Americans as in Caucasians at high risk for DGF [abstract]. Am J Transplant. 2003;3(suppl 5):555.
5. Budde K, Schmouder RL, Brunkhorst R, et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol. 2002;13:1073-1983.
6. Zimmerlin AG, Patten CJ. Role of CYP4F in the metabolic clearance of FTY720: prediction of low drug to drug interaction potential [abstract]. Transplantation. 2000;69(suppl):S191.
7. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. 1999;438:642-648.
8. Kovarik JM, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004;57:586-591.
9. Urien S, Bastian G, Lucas C, Bizzari JP, Tillement JP. Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets: usefulness of an erythrocyte partitioning technique. Invest New Drugs. 1992;10:263-268.
10. Budde K, Schmouder RL, Nashan B, et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am J Transplant. 2003;3:846-854.
11. Hongshan L, Meno-Tetang GML, Ciba K, et al. Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses. J Pharmacol Exp Ther. 2002;301:519-526.